1. Home
  2. CLB vs ANNX Comparison

CLB vs ANNX Comparison

Compare CLB & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core Laboratories Inc.

CLB

Core Laboratories Inc.

HOLD

Current Price

$18.61

Market Cap

864.2M

Sector

N/A

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.81

Market Cap

918.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLB
ANNX
Founded
1936
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
864.2M
918.2M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
CLB
ANNX
Price
$18.61
$5.81
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$12.50
$16.50
AVG Volume (30 Days)
370.2K
2.3M
Earning Date
02-04-2026
03-02-2026
Dividend Yield
0.22%
N/A
EPS Growth
2.46
N/A
EPS
0.68
N/A
Revenue
$526,520,000.00
N/A
Revenue This Year
$3.64
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$27.45
N/A
Revenue Growth
0.51
N/A
52 Week Low
$9.72
$1.29
52 Week High
$20.36
$7.18

Technical Indicators

Market Signals
Indicator
CLB
ANNX
Relative Strength Index (RSI) 55.05 46.79
Support Level $16.98 $5.43
Resistance Level $20.05 $6.59
Average True Range (ATR) 0.82 0.42
MACD -0.15 -0.15
Stochastic Oscillator 65.98 16.57

Price Performance

Historical Comparison
CLB
ANNX

About CLB Core Laboratories Inc.

Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: